Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Johnson

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in RatsRebecca I Erickson, Leah K Schutt, Jacqueline M Tarrant, et al.
Science Translational Medicine|November 4, 2016
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunityCalliope A Dendrou, Adrian Cortes, Lydia Shipman, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
A reversed sulfonamide series of selective RORc inverse agonistsMonique B van Niel, Benjamin P Fauber, Matthew Cartwright, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.
Bioorganic & Medicinal Chemistry Letters|April 27, 2023
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug designJames J Crawford, Jianwen Feng, Hans D Brightbill, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Nature|March 4, 2011
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Ingrid E Wertz, Saritha Kusam, Cynthia Lam, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisMark E Schnute, Patrick M O'Brien, Joe Nahra, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in RatsRebecca I Erickson, Leah K Schutt, Jacqueline M Tarrant, et al.
Science Translational Medicine|November 4, 2016
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunityCalliope A Dendrou, Adrian Cortes, Lydia Shipman, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
A reversed sulfonamide series of selective RORc inverse agonistsMonique B van Niel, Benjamin P Fauber, Matthew Cartwright, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2013
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitorsSue J Sohn, Kathy Barrett, Anne Van Abbema, et al.
Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.
Bioorganic & Medicinal Chemistry Letters|April 27, 2023
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug designJames J Crawford, Jianwen Feng, Hans D Brightbill, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Nature|March 4, 2011
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Ingrid E Wertz, Saritha Kusam, Cynthia Lam, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisMark E Schnute, Patrick M O'Brien, Joe Nahra, et al.
Pageof 6